Background
Methods
Search strategy
Inclusion criteria
Data extraction
Quality assessment
Statistical analysis
Results
Literature search and study characteristic
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Iqbal U [47], 2017, China | M/F | 2001–2011 | The Taiwan NHI database | 22,574 | 90,296 | Gastric cancer | Prescription | Use at least for 2 months during the 3-year period before the initial cancer diagnosis | 1,2,13,14,15,16,17 | 7 |
Wang Y [48], 2015, China | M/F | 2005–2010 | Population from China | 175 | 350 | Gastric cancer | Structured questionnaire | Use at least once a week for one year (regular) | 2,3,5,6,7,10,18,19,20 | 7 |
Gong EJ [49], 2014, Korea | M/F | 2000–2010 | Asian Medical Center | 327 | 327 | Gastric cancer | Self-administered questionnaire | Use of aspirin - not further defined | 1,2,3,4,6,8,10,11,12,18,21,22,23, | 6 |
Bertuccio P [50], 2010, Italy | M/F | 1997–2007 | Population from Italy | 229 | 543 | Gastric cancer | Structured questionnaire | Use at least once a week for more than 6 months (regular) | 1,2,4,5,6,10,24 | 7 |
Figueroa JD [51], 2009, US | M/F | 1993–1995 | Population from Connecticut, New Jersey, and western Washington state | 367 | 695 | Gastric adenocarcinomas | Structured interviews | Use at least once per week for 6 months or more | 1,2,3,10,25,26 | 7 |
Duan L [52], 2008, US | M/F | 1992–1997 | Los Angeles County Cencer Surveillance Program | 718 | 1356 | Gastric adenocarcinoas | Structured questionnaire | Use of aspirin - not further defined | 1,2,3,5,10,20,25,27,28 | 7 |
Fortuny J [53], 2007, US | M/F | 1980–2002 1993–2004 | GHC and HFHS | 496 | 3996 | Gastric cancer | Outpatient pharmacy records | No prescription for aspirin (never users) | 1,2,25,29,30 | 7 |
Akre K [54], 2001, Sweden | M/F | 1989–1995 | Population from Swedish counties | 567 | 1165 | Gastric cancer | Interviews | Ever use of aspirin (ever users) | 1,2,9 | 7 |
Coogan PF [55], 2000, US | M/F | 1977–1998 | Population from Baltimore, Boston, New York, and Philadelphia | 254 | 5952 | Stomach cancer | Administered questionnaires | Use at least 4 days/week for at least 3 months (regular) | 1,2,3,4,5,6,25,32,33,34 | 8 |
Zaridze D [56], 1999, Russia | M/F | 1993–1997 | Moscow City Oncology Hospital and Cancer Research Center and were Moscow City residents | 448 | 610 | Stomach cancer | Self-administered questionnaire | Use at least 2 days a week for 6 months or more (regular) | 1,5 | 6 |
Cohort studies | ||||||||||
Kim YI [57], 2016, Koreaa | M/F | 2004–2010 | KNHI database | 117 | 11,598 | Gastric cancer | Prescription database | Never make claims for aspirin prescription or less than 6 months of aspirin prescriptions (non-users) | 1,2,20, 35 | 7 |
Lee J [58], 2012, Korea | M/F | 1999–2008 | Samsung Medical Center | 184 | 347 | Gastric cancer | Prescription | Have aspirin fill prescriptions for at least 6 months | 1,2,14 | 6 |
Abnet CC [59], 2009, US | M/F | 1995–2003 | AARP | 360 | 311,115 | Gastric cancer | Questionnaire | Any use in the past 12 months | 1,2,3,5,6,10,34,36,37 | 7 |
Epplein M [60], 2009, US | M/F | 1993–2004 | Multiethnic Cohort (Hawaii and Los Angeles, California) | 643 | 169,292 | Gastric cancer | Self-administered questionnaire | Use any aspirin at least 2 times a week (for 1 month or longer) | 1,2,3,6,10,25 | 7 |
Lindblad M [61], 2005, UKa | M/F | 1994–2001 | General Practitioners Research Database | 1023 | 1000 | Gastric Cancer | Prescription database | Any recorded use of aspirin (ever use) | 1,2,3,6,10,28, 31 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 68 | 29,470 | Stomach cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 39 | 12,668 | Stomach cancer | Self-reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Figueroa JD [51], 2009, US | M/F | 1993–1995 | Population from Connecticut, New Jersey, and western Washington state | 282 | 695 | Oesophageal cancer | Structured interviews | Use at least once per week for 6 months or more | 1,2,3,10,11,12 | 7 |
Sadeghi S [64], 2008, Australia | M/F | 2001–2005 | Population from Australia | 1102 | 1580 | Oesophageal cancer | Questionnaire | Use at least once a week for duration of 6 months or more(regular) | 1,2,4,6,10,16,28,29 | 6 |
Duan L [52], 2008, US | M/F | 1992–1997 | Los Angeles County Cencer Surveillance Program | 220 | 1356 | Esophageal adenocarcinoma | Structured questionnaire | Use of aspirin - not further defined | 1,2,3,5,10,11,14,15,16, | 7 |
Fortuny J [53], 2007, US | M/F | 1980–2002 1993–2004 | GHC and HFHS | 277 | 3996 | Oesophageal cancer | Outpatient pharmacy records | No prescription for aspirin (never users) | 1,2,11,17,18 | 7 |
Ranka S [65], 2006, UK | M/F | 1999–2004 | Population from Norfolk | 411 | 1644 | Oesophageal cancer | Self-reported,medical admission notes and nursing records | Use of aspirin - not further defined | 3,6 | 8 |
Anderson LA [66], 2006, Ireland | M/F | 2002–2004 | The FINBAR study | 224 | 260 | Esophageal adenocarcinoma | Interview | Use aspirin at least once weekly for ≥ 6 months | 1,2,3,5, 6,10,30,31, | 6 |
Jayaprakash V [67], 2006, US | M/F | 1982–1998 | RPCI | 163 | 482 | Oesophageal cancer | Questionnaire | Use at least once a week for 6 months (regular) | 1,2,3,6,10,32, | 6 |
Sharp L [68], 2001, UK | F | 1993–1996 | Population in England and Scotland | 159 | 159 | Oesophagus squamous cell carcinoma | Interview | Daily use of aspirin for at least a month | 1,33 | 7 |
Cohort sutdies | ||||||||||
Macfarlane TV [69], 2014, UKa | M/F | 1996–2010 | PCCIU database | 1197 | 3585 | Oesophageal cancer | Prescription database | Had at least one Prescription (users) | 1,2,13,23,24,25,26,27 | 7 |
Abnet CC [59], 2009, US | M/F | 1995–2003 | AARP | 228 | 311,115 | Oesophageal adenocarcinoma | Questionnaire | Any use in the past 12 months | 1,2,3,5,6,10,20,21,22 | 7 |
Lindblad M [61], 2005, UKa | M/F | 1994–2001 | GPRD database | 909 | 1000 | Esophageal cancer | Prescription database | Any recorded use of aspirin (ever use) | 1,2,3,6, 10,14, 19 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population of North Jutland County | 26 | 29,470 | Oesophagus cancer | Prescription database | 75–150 mg once daily (low-dose aspirin) | 1,2 | 8 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Iqbal U [47], 2017, China | M/F | 2001–2011 | The Taiwan NHI database | 86,597 | 346,388 | Colorectal cancer | Prescription | Patients had aspirin prescribed at least for 2 months during the 3-year period before the initial cancer diagnosis | 1,2,13,14,15,16,17 | 7 |
Friis S [70], 2015, Dermark | M/F | 1994–2011 | Danish Cancer Registry, Aarhus University Prescription Database, Danish National Patient Registry, Danish Civil Registration System | 10,280 | 10,280 | Colorectal cancer | Prescription database | Have 2 or more prescriptions for aspirin(ever use) | 1,2,14,26,27,28,29,30,31,32,33. | 8 |
Rennert G [71], 2010, Israel | M/F | 1988–2006 | The MECC | 2648 | 2566 | Colorectal cancer | Interviewed | Daily aspirin use for at least 3 years | 1,2,7,26 | 5 |
Din FV [72], 2010, UK | M/F | 2001–2008 | SCCS | 2279 | 2907 | Colorectal cancer | Questionnaire | Use > 4 tablets/week for > 1 month | 1,2,3,6,8,18,19,34,35 | 4 |
Harris RE [73], 2008, US | M/F | 2003–2004 | The CHRI | 326 | 652 | Colon cancer | Questionnaire | Use at least once per week for more than 1 year | 1,3,4,6,7,8,26,36 | 5 |
Kim S [74], 2008, US | M/F | 2001–2006 | North Carolina Colon Cancer Study II | 1057 | 1019 | Colorectal cancer | Questionnaire | Any use of aspirin in the past 5 years (ever users) | 1,2,7, 8,18,37, 38,39,40 | 6 |
Hoffmeister M [75], 2007, Germany | M/F | 2003–2004 | The Rhine–Neckar–Odenwald region in the South-West of Germany | 477 | 517 | Colorectal cancer | Questionnaire | Use at least 2 times per week for at least 1 year(current regular use) | 1,2,3,4,5,6,8,22,27,30,41,42,43 | 8 |
Slattery ML [76], 2006, US | M/F | 1991–1994 | KPMCP | 2351 | 2972 | Colorectal cancer | Questionnaire | Use at least three times a week for 1 month(regular) | 1,2,7 | 7 |
Macarthur M [77], 2005, UK | M/F | 1998–2000 | Grampian Health Board residents | 264 | 408 | Colorectal cancer | Questionnaire | Use aspirin every day for a month or more(regular) | 1,2 | 6 |
Juarranz M [78], 2002, Spain | M/F | 1995–1996 | The Research Unit of the Council of Health and Social Services of the Community ofMadrid | 196 | 228 | Colon cancer | Questionnaire | Consider aspirin use as a continuous numeric variable in milligrams/week -not further defined | 1,2 | 8 |
Evans RC [79], 2002, UK | M/F | – | Merseyside and Cheshire Cancer Registry | 512 | 512 | Colorectal cancer | Questionnaire | Use at least once per day(regular) | 1,2,26,38 | 8 |
Neugut AI [80], 1998, US | M/F | 1989–1992 | Columbia-Prebyterian Medical Center | 256 | 322 | Colon cancer | Medical record | Use aspirin-not further defined | 1,4,5 | 6 |
Rosenberg L [81], 1998, US | M/F | 1992–1994 | Hospital in Massachusetts | 942 | 935 | Large bowel carcinoma | Questionnaire | Use at least 4 days a week for at least 3 months | 1,2 | 9 |
La VC [82], 1997, Italy | M/F | 1992–1996 | Population from Italian areas | 1357 | 1891 | Colorectal adenoma | Questionnaire | Use more than four times per week for > 6 months | 1,2,5,6,8,18,26,34, 43 | 7 |
Reeves MJ [83], 1996, US | F | 1991–1992 | Wisconsin Cancer Reporting system | 21 | 22 | Colorectal cancer | Self-reported | Use at least one table twice weekly or more than at least 12 months | 1,4,8,30 | 8 |
Suh O [84], 1993, US | M/F | 1982–1991 | Roswell Park Tumor Registry and Diagnostic Index | 830 | 1662 | Colorectal adenoma | Questionnaire | Use aspirins for at least 1 year(users) | 1,2,5,26 | 9 |
Kune GA [85], 1988, Australia | M/F | 1980–1981 | Population in Melbourne | 715 | 727 | Colorectal adenoma | Questionnaire, hospital records, and interview | Use aspirin “daily” “weekly” or “don’t know- not further defined” | 1,2 | 8 |
Cohort studies | ||||||||||
Park SY [86], 2017, US | M/F | 1993–2012 | The MEC Study | 3879 | 183,199 | Colorectal cancer | Questionnaire | Had ever use of aspirin | 1,3,4,6,8,18,19,27,30,34,37,43, 48,49 | 8 |
Kim C [87], 2016, US | M | 1982–2000 | Physicians Health Study | 268 | 446 | Colorectal cancer | Questionnaire | Use of aspirin- not further defined | 6,8,18,19, 20 | 9 |
Soriano LC [88], 2016, UK(STUDY 1) | M/F | 2000–2011 | THIN | 3033 | 10,000 | Colorectal cancer | Prescription | No recorded use at any time(non user) | 1,2,3,8,21, 22,24,25 | 9 |
Soriano LC [88], 2016, UK(STUDY 2) | M/F | 2001–2012 | THIN | 3174 | 10,000 | Colorectal cancer | Prescription | No recorded use at any time(non user) | 1,2,3,8,21,22,23 | 9 |
Soriano LC [88], 2016, UK(STUDY 3) | M/F | 2001–2012 | THIN | 12,333 | 20,000 | Colorectal cancer | Prescription | No recorded use at any time(non user) | 1,2,3,8,21,22 | 9 |
Vaughan LE [89], 2016, US | F | 2004–2011 | IWHS | 218 | 14,386 | Colon cancer | Questionnaire | Never use aspirin (non-user) | 1,3,8,22 | 8 |
Cao Y [8], 2016, US | M/F | 1980–2010 1986–2012 | NHS and HPFS | 2895 | 135,965 | Colorectal cancer | Questionnaire | Use at least 2 times per week(regular) | 3,4,6,7,8,18,19,27,30,34,37,42,43,49,50,51,52,53 | 9 |
Lin CC [90], 2015, Chinaa | M/F | 2000–2009 | The Longitudinal Health Insurance Database | 467 | 60,828 | Colorectal cancer | Prescription database | Use any low-dose aspirin (75–165 mg) | 1,2,54,55 | 8 |
Hollestein LM [91], 2014, Netherlandsa | M/F | 1998–2010 | PHARMO and the Eindhoven Cancer Registry | 972 | 109,276 | Colorectal cancer | Prescription database | Low dose aspirin (≤100 mg daily)- not further defined | 1,2,56,72 | 8 |
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 1397 | 140,933 | Colorectal cancer | Self-administered questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5,6,7,8,37,18,19,22,26,27,33,43,50,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71 | 9 |
Brasky TM [93], 2012, US | M/F | 2002–2008.12.30 | The VITAL | 451 | 64,847 | Colorectal cancer | Questionnaire | Use ≥1 day/week for ≥ 1 year(regular) | 1,3,4,5,6,7,8,9,10,18,19,22,28,30,33,42,43, 50,67,68,69,71 | 8 |
Ruder EH [94], 2011, US | M/F | 1996–2006 | National Institutes of Health-AARP Diet and Health Study | 3894 | 301,240 | Colorectal cancer | Self-administered questionnaire | Use aspirin during the previous 12 months | 1,2,3,4,5, 6,7,8,18,27 | 7 |
Friis S [95], 2009, Denmark | M/F | 1995–2006 | Danish Diet, Cancer, and Health Study | 615 | 51,053 | Colorectal cancer | Questionnaire | Use fewer than 2 pills per month (nonuse) | 1,2,6,8,14,22,27,30, | 7 |
Siemes C [96], 2008, Netherlands | M/F | 1992–2004 | The Rotterdam Study | 195 | 7621 | Colorectal cancer | Questionnaire and prescriptions | The absence of a prescription for any non-aspirin or aspirin NSAID(no use) | 1,2,3,8,18, 27,34,70,73,74 | 8 |
Vinogradova Y [97], 2007, UKa | M/F | 1995–2005 | QRESEARCH database | 1226 | 5369 | Colorectal cancer | Prescription database | Receive ≥1 prescription for aspirin in the 13 to 48 months before index date | 3, 8,22,41 | 8 |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 1861 | 146,113 | Colorectal cancer | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,7,18,22,27,28,30,36,68,52,53 | 8 |
Larsson SC [99], 2006, Sweden | M/F | 1998–2005 | Swedish Mammography Cohort and Cohort of Swedish Men | 705 | 74,250 | Colorectal cancer | Questionnaire | Aspirin use- not further defined | 1,2,3,4,5,8,18 28 | 9 |
Muscat JE [100], 2005, US | M/F | 1983–1999 | The Framingham Heart study | 145 | 433 | Colorectal cancer | Questionnaire | Never/< 1/week, 1–3/week, > 3/week | 1,2,3,44 | 9 |
Rahme E [101], 2003, Canada | M/F | 1997–2001 | RAMQ | 179 | 2568 | Colorectal adenoma | Prescription | Use at least 1 year | 45,46,47 | 7 |
Rodríguez LAG [102], 2001, UKa | M/F | 1994–1997 | The GPRD | 2002 | 943,903 | Colorectal cancer | Prescription database | Never received a single prescription(non-user) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 169 | 12,668 | Colorectal cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Paganini-Hill A [103], 1989, US | M/F | 1981–1988 | Population from Leisure World, Laguna Hills, US | 181 | 13,870 | Colon cancer | Questionnaire | Aspirin use: none,<daily, daily | 2 | 4 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Choi J [104], 2016, US | M/F | 2000–2014 | Patients seen at the Mayo Clinic | 2395 | 4769 | Cholangiocarcinoma | Electronic medical record | Use at least once per week at the index date | 1,2,3,11,12,13,14,15 | 9 |
Yang B [105], 2016, UK | M/F | 1988–2011 | CPRD | 814 | 3180 | Primary liver cancer | Medical records database | Had two or more aspirin prescriptions recorded prior to the index date(ever use) | 3,6,10,15,16,17,18 | 7 |
Burr NE [106], 2014, UK | M/F | 2004–2010 | NNUH and LGH | 81 | 275 | Cholangiocarcinoma | Letters from general practitioners (GPs), hospital clerkings, surgical records, nursing notes and radiological reports | Drug was recorded in any of the data sources | 1,2,3,15 | 7 |
Cohort studies | ||||||||||
Kim G [107], 2017, Korea | M/F | 2003–2012 | NHIS-NSC | 229 | 1145 | Hepatocellular carcinoma | Prescription | At least one prescription of aspirin between the cohort entry and the index date | 1,2,19,20, | 6 |
Petrick JL [108], 2015, US | M/F | from 1993 | AARP,AHS, USRT,BCDDP, PLCO,HPFS, CPSII, BWHS WHI,NHS | 904 | 1,084,133 | Hepatocellular carcinoma and intrahepatic cholangiocarcinoma | Questionnaire | Any reported aspirin use in the 12 months prior to baseline | 1,2,3,6,10,11,15, 21 | 7 |
Liu E [109], 2005, China | M/F | 1997–2001 | Population from Shanghai | 368 | 1013 | Gallbladder Cancer | Questionnaire | Use at least twice a week for longer than a month 1 year before interview | 1,2,5, 22 | 6 |
S Friis [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 21 | 29,470 | Liver cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Risch HA [110], 2017, China | M/F | 2006–2011 | Our Shanghai study | 761 | 794 | Pancreatic cancer | In-person questionnaire interviews | Use at least one tablet per week for 3 months or longer(regular) | 1,2,3,5,7,10,50,51 | 7 |
Kho PF [111], 2016, Australia | M/F | 2007–2011 | The QPCS | 522 | 652 | Pancreatic cancer | Questionnaire | Long-term use of aspirin ((> 2 years) | 1,2,3,6,10 | 8 |
Streicher SA [112], 2014, US | M/F | 2005–2009 | Population from Connecticut | 360 | 682 | Pancreatic cancer | Questionnaire | Use at least once a week on average, for 3 months or more | 1,2,3,5,7,10,11,52 | 8 |
Tan XL [113], 2011, US | M/F | 2004–2010 | Patients from the Mayo Clinic | 740 | 1043 | Pancreatic cancer | Questionnaire | Use aspirin ≥1 day per month | 1,2,3,7,10 | 6 |
Pugh TFG [114], 2011, UK | M/F | 2004–2007 | Clinical management databases in Norfolk and Leicestershire | 206 | 251 | Pancreatic cancer | Medical records | Use of aspirin - not further defined | 1,2,3,7 | 6 |
Bonifazi M [115], 2010, Italy | M/F | 1991–2008 | Patients in in the province of Pordenone and in the greater Milan area, northern Italy | 308 | 477 | Pancreatic cancer | Questionnaire | Use at least once a week for more than 6 months(regular) | 1,2,3,5,7,10,53,54 | 8 |
Menezes RJ [116], 2002, US | M/F | 1982–1998 | The RPCI | 194 | 585 | Pancreatic cancer | Patient Epidemiology Data System (PEDS) and questionnaire | Use at least once a week for six consecutive months(regular) | 1,3,4 | 5 |
Cohort studies | ||||||||||
Cao Y [8], 2016, US | M/F | 1980–2010 1986–2012 | NHS and HPFS | 607 | 135,965 | Pancreatic cancer | Questionnaire | Use at least 2 times per week(regular) | 3,4,6,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24 | 9 |
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 397 | 142,330 | Pancreatic cancer | Self-administered questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5, 6,10,11,17,18,19,25,26,28,29,30,31,32,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48 | 9 |
Bradley MC [117], 2010, UKa | M/F | 1995–2006 | GPRD | 564 | 3984 | Pancreatic cancer | Prescription Database | Use 300 mg or more a day (high-dose) | 3,6,7,10, 25,27,47,55, | 8 |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 404 | 146,113 | Pancreatic cancer | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,7,10,11, 15,16,17,18,20,25, 45, 49 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 62 | 29,470 | Pancreatic cancer | Prescription Database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Anderson KE [118], 2002, US | F | 1992–1999 | IWHS | 80 | 28,283 | Pancreatic cancer | Questionnaire | Never use any type of medication (never use) | 1,3,7,19 | 7 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 30 | 12,668 | Pancreatic cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Iqbal U [47], 2017, China | M/F | 2001–2011 | The Taiwan NHI database | 68,409 | 273,636 | Lung cancer | Prescription | Patients had aspirin prescribed at least for 2 months during the 3-year period before the initial cancer diagnosis | 1,2,13,14,15,16,17 | 7 |
Lim WY [119], 2012, Singapore | F | 2005–2008 | Population from Chinese | 252 | 556 | Lung cancer | Questionnaire | Use twice a week or more, for a month or more(regular) | 1, 3,4,5,19,34 | 7 |
McCormack VA [120], 2011, US | M/F | – | AHFTS | 977 | 683 | Lung cancer | Interview | – | 1,3,5,11 | 7 |
McCormack VA [120], 2011, US | M/F | – | Population from Boston | 768 | 123 | Lung cancer | – | – | 1,3,5,11 | 7 |
McCormack VA [120], 2011, US | M/F | – | Population from Florida | 467 | 889 | Lung cancer | – | – | 1,3,5,11 | 7 |
McCormack VA [120], 2011, US | M/F | – | Population from Hawaii | 629 | 588 | Lung cancer | – | – | 1,3,5,11 | 7 |
McCormack VA [120], 2011, US | M/F | – | MSKCC | 102 | 101 | Lung cancer | – | – | 1,3,5,11 | 7 |
McCormack VA [120], 2011, US | M/F | – | NELCS | 276 | 251 | Lung cancer | – | – | 1,3,5,11 | 7 |
McCormack VA [120], 201, Israel | M/F | – | NICCC | 280 | 270 | Lung cancer | – | – | 1,3,5,11 | 7 |
Kelly JP [121], 2008, US | M/F | 1976–2007 | Patients in Boston Baltimore New York and Philadelphia | 1884 | 6251 | Lung cancer | In-person interview | Use at least 4 days per week for at least three continuous months(regular) | 1,2,3,4,6,29, 30,36 | 6 |
Van Dyke AL [122], 2008, US | F | 2001–2005 | Metropolitan Detroit Cancer Surveillance System, a participant in the National Cancer Institute’s Surveillance | 580 | 541 | Lung Cancer | Questionnaire | Had taken any aspirin | 1,3,4,5,10,11, 3135,37 | 7 |
Harris RE [123], 2007, US | M/F | 2002–2004 | The Ohio State University Medical Center, Columbus, Ohio | 375 | 654 | Lung Cancer | Interview | Use no more than one pill per week for less than 1 year(nonuser) | 1,2,3,5,6,10,11,35 | 7 |
Muscat JE [124], 2003, US | M/F | 1992–2000 | Hospitals in New York and Washington, D.C | 997 | 918 | Lung Cancer | Questionnaire | Use three tablets per week for 1 or more years(regular) | 1,2,3,4 | 7 |
Moysich KB [125], 2002, US | M/F | 1982–1998 | RPCI | 868 | 935 | Lung Cancer | Epidemiological questionnaire | Use at least once a week for one year(regular) | 1,3,4 | 8 |
Cohort studies | ||||||||||
Cao Y [8], 2016, US | M/F | 1980–2010 1986–2012 | NHS and HPFS | 2430 | 135,965 | Lung cancer | Questionnaire | Use at least 2 times per week(regular) | 3,5,6,7,8,9,10,11,12,18,19,20,21,22,23,24,25,28 | 9 |
F | 1993–2010 | WHI | 1902 | 143,841 | Lung cancer | Questionnaire | Use at least twice a week in each of the two weeks preceding the interview(regular) | 1,3,5,6,10,11,19,25,31,50,51,52 | 8 | |
Hollestein LM [91], 2014, Netherlandsa | M/F | 1998–2010 | PHARMO and the Eindhoven Cancer Registry | 915 | 109,276 | Lung cancer | Prescription database | Low dose aspirin (≤ 100 mg daily)- not further defined | 1,2,26,27 | 8 |
Brasky TM [127], 2012, US | M/F | 2000–2007 | The VITAL cohort | 100 | 69,919 | Lung cancer | The baseline questionnaire | Use aspirin ≥1 day/week for ≥ 1 year(regular) | 1,2,3,4,5,10,11, 29,35,46,53,54 | 8 |
McCormack VA [120], 2011, US | M/F | – | DDCHS | 812 | 55,396 | Lung cancer | Questionnaire | – | 1,3,5,11, | 7 |
Siemes C [96], 2008, Netherland | M/F | 1992–2004 | The Rotterdam Study | 134 | 7621 | Lung cancer | Questionnaire and prescriptions. | The absence of a prescription for any non-aspirin or aspirin NSAID(no use) | 1,2,10,18,21,25, 35,55,56,57 | 8 |
Olse JH [128], 2008, Dermarka | M/F | 2002–2005 | Danish Diet, Cancer and Health prospective cohort study | 282 | 390 | Lung cancer | Questionnaire and prescription database | Any use of aspirin or 1 year or more before the index date | 1,2,3,4,38,39 | 7 |
Hernández-Díaz S [129], 2007, UKa | M/F | 1995–2004 | THIN database | 4336 | 10,000 | Lung cancer | THIN database | Had recorded prescription at any time before the index date | 1,2,3,6,10, 14,33,35,40,41,42,43,44,45,46,47,48 | 8 |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 1815 | 146,113 | Lung cancer | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,4,9,10,11, 18,25,28,29, 31,32,33 | 8 |
Hayes JH [130], 2006, US | F | 1992–2002 | IWHS | 403 | 27,162 | Lung cancer | Questionnaire | Never, less than one weekly, once weekly, two to five times weekly, and six or more times weekly | 1,3,4,6,10,19, 29,58 | 7 |
Akhmedkhanov A [131], 2002, US | F | 1994–1996 | NYU and Women’s Health Study cohort. | 81 | 808 | Lung cancer | Questionnaire | Use three or more times per week for a period of 6 months or longer | 1,3,4,49 | 7 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 163 | 12,668 | Lung cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Paganini-Hill A [103], 1989, US | M/F | 1981–1988 | Population in Leisure World, Laguna Hills, US | 111 | 13,870 | Lung cancer | Questionnaire | Aspirin use: none,<daily, daily | 2 | 4 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Iqbal U [47], 2017, China | F | 2001–2011 | The Taiwan NHI database | 65,491 | 435,364 | Breast cancer | Prescription | Patients had aspirin prescribed at least for 2 months during the 3-year period before the initial cancer diagnosis | 1,2,13,14, 15,16,17 | 7 |
Dierssen-Sotos T [132], 2016, Spain | F | 2008–2013 | The MCC study | 1736 | 1909 | Breast cancer | Questionnaire | Use of aspirin- not further defined | 1,3,4,5,10,30,36,40,50,51 | 8 |
Cui Y [133], 2014, US | F | 2001–2011 | Nashville Breast Health Study | 2154 | 1831 | Breast cancer | Telephone interview | Use aspirin three or more times a week for a minimum duration of 1 year(regular) | 1,3,4,5,6,11,18,25,40,50,51,52,53 | 7 |
Brasky TM [134], 2010, US | F | 1996–2001 | WEB Study | 1057 | 2094 | Breast cancer | Self-reported | Use 0 days/month (non-users) | 1,4,5,11,25,29,36,37,38,53, | 6 |
Cronin-Fenton DP [135], 2010, Denmark | F | 1991–2006 | Population from North Jutland and Aarhus counties, Denmark | 8195 | 81,950 | Breast cancer | Danish healthcare databases | Use at least 2 prescriptions within 2 years of diagnosis(recent use) | 25,31,39 | 8 |
Slattery ML [136], 2007, US | F | 1999–2004 | Population from the southwestern United States (4-Corner’s Breast Cancer Study) | 2325 | 2525 | Breast cancer | Questionnaire | Use at least thrice weekly for at least 1 month(regular) | 1,10,18,38,54,55,56 | 7 |
Harris RE [137], 2006, US | F | 2003–2004 | CHRI | 277 | 493 | Breast cancer | Questionnaire | Use at least two times per week for 2 years or more | 1,3,5,6,10,38,51 | 7 |
Swede H [138], 2005, US | F | 1982–1998 | The Roswell Park Cancer Institute | 1478 | 3383 | Breast cancer | Questionnaire | Use aspirin at least once a week for at least 1 year(regular) | 5,10,36,40,53 | 6 |
Zhang YQ [139], 2005, US | F | 1976–2002 | The Case-Control Surveillance Study Revisited | 2406 | 1554 | Breast cancer | Questionnaire | Use at least four times per week for 3 or more continuous months(regular) | 1,4,5,6,10,11, 36,37,38,40,41,53,54,61,62,63,64 | 5 |
Terry MB [140], 2004, US | F | 1996–1997 | The Long Island Breast Cancer Study Project | 1442 | 1420 | Breast cancer | Questionnaire | Use at least once a week for 6 months or longer(ever use) | 1,10,29,31 | 6 |
Moorman PG [141], 2003, US | F | 1996–2000 | Phase II of the Carolina Breast Cancer and Carcinoma In Situ Study | 500 | 2631 | Breast cancer | Questionnaire | Use at least 8 days a month for three or more months(regular) | 1 | 6 |
Cotterchio M [142], 2001, Canada | F | 1996–1998 | Population in Canada | 2696 | 2600 | Breast cancer | Questionnaire | Daily use for≥ 2 months(any use) | 1,39,53 | 6 |
Neugut AI [80], 1998, US | F | 1989–1992 | Columbia-Prebyterian Medical Center | 252 | 176 | Breast cancer | Medical record | Use aspirin-not further defined | 1,4,5 | 6 |
Cohort studies | ||||||||||
Cao Y [8], 2016, US | F | 1980–2010 1986–2012 | NHS and HPFS | 7424 | 135,965 | Breast cancer | Questionnaire | Use at least 2 times per week(regular) | 3,5,6,7,8,9,10,11,12,18,19,20,21,22,23,24,25,28 | 9 |
Kim S [143], 2015, US | F | 2003–2013 | Sister Study | 2118 | 50,884 | Breast cancer | Questionnaire | Use at least once a week(current user) | 4,5,10,11,40,51,53, 67 | 8 |
Hollestein LM [91], 2014, Netherlandsa | F | 1998–2010 | PHARMO and the Eindhoven Cancer Registry | 585 | 55,597 | Breast cancer | Prescription database | Low dose aspirin (≤ 100 mg daily)- not further defined | 1,2,26,27 | 8 |
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 5401 | 142,330 | Breast cancer | Self-administered questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5, 6,7,10,11,18,19,22,24,25,29,30,31,,32,33,34,35,36,37,38,39,40,4142,43,44,45,46,47 | 9 |
Bardia A [144], 2011, US | F | 1986–2005 | The IWHS | 1581 | 26,580 | Breast cancer | Questionnaire | Ever use aspirin- not further defined | 1,3,4,5,6,10, 18,25,36,37,38,39,40,68,69 | 8 |
Bosco JL [145], 2011, US | F | 1995–2007 | BWHS | 1275 | 59,000 | Breast cancer | Questionnaire | Use aspirin ≥ 3 days per week (regular) | 1,3,4,10,18,25,29,70 | 9 |
Eliassen AH [146], 2009, US | F | 1989–2003 | NHS II | 1229 | 112,292 | Breast cancer | Questionnaire | Use aspirin ≥2 times per week(regular) | 5,6,7,10,36,38,40,53, 68,71 | 9 |
Friisa S [147], 2008, Denmark | F | 1993–2003 | The prospective Diet, Cancer and Health cohort study | 396 | 28,695 | Breast cancer | Questionnaire | Use more than one pill per month | 1,4,25,38,50,53 | 7 |
Gierach GL [148], 2008, US | F | 1995–2003 | AARP | 4451 | 126,124 | Breast cancer | Questionnaire | Ever use aspirin- not further defined | 1,5,6,11,25,29,40,49, 72 | 7 |
Ready A [149], 2008, US | F | 2000–2004 | VITAL cohort | 479 | 35,323 | Breast cancer | Questionnaire | Use at least once a week for a year during the last 10 years(any use) | 1,5,6,10,11,19,28,29,36,37,40,72, 73,74 | 7 |
Siemes C [96], 2008, Netherland | F | 1992–2004 | The Rotterdam Study | 175 | 7621 | Breast cancer | Questionnaire and prescriptions. | The absence of a prescription for any non-aspirin or aspirin NSAID(no use) | 1,3,10,25,36,37,50, 75 | 8 |
Jacobs EJ [98], 2007, US | F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 3121 | 76,303 | Breast cancer | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,3,4,10,11,18,20,25, 28,29,45,48,49 | 8 |
Gill JK [150], 2007, US | F | 1993–2002 | Multiethnic Cohort | 1457 | 98,920 | Breast cancer | Questionnaire | Use at least two times per week for 1 month or longer | 1,4,5,6,10,11, 25,28,36,37,40,50,51,76 | 7 |
Gallicchio L [151], 2007, US | F | 1989–2006 | CLUE II (“Give us a Clue to Cancer and Heart Disease”) | 418 | 15,651 | Breast cancer | Questionnaire | Use aspirin in the last 48 h(current user) | 1 | 7 |
Marshall SF [152], 2005, US | F | 1995–2001 | The California Teachers Study | 2391 | 114,640 | Breast cancer | Questionnaire | Use at least once a Week(regular) | 1,3,5,6,10,11,18, 25,28,51,53,59,77 | 9 |
Rahme E [153], 2005, Canadaa | F | 1998–2202 | RAMQ | 664 | 23,573 | Breast cancer | Prescription database | Ever use aspirin during the year prior to the index date | 1,25,28,53,57,58,60 | 7 |
Rodríguez LA [154], 2004, UKa | F | 1995–2001 | GPRD | 3708 | 23,708 | Breast cancer | Prescription database | No recorded use at any time before the index date(nonuser) | 1,3,6,10,25,29,53, 62,65,66 | 8 |
Harris RE [155], 1999, US | F | 1991–1996 | Population from The Ohio State University Comprehensive Cancer Center in Columbus, Ohio | 316 | 32,505 | Breast cancer | Questionnaire | Use aspirin ≥1 pill per week | 1 | 5 |
Schreinemachers DM [63], 1994, US | F | 1971–1987 | The National Health and Examination Survey Ι | 147 | 12,668 | Breast cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Paganini-Hill A [103], 1989, US | F | 1981–1988 | Population from Leisure World, Laguna Hills, US | 214 | 13,870 | Breast cancer | Questionnaire | Aspirin use: none,<daily, daily | 2 | 4 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Peres LC [156], 2016, US | F | 2010–2015 | AACES | 541 | 731 | Epithelial ovarian cancer | Questionnaire | Use at least once a week or at least 5 days out of the month, at any point in their lifetime(regular) | 1,4,5,10,18, 29,48,49,50,51,52,53,54,55 | 7 |
Baandrup L [157], 2015, Denmark | F | 2000–2011 | The Danish Cancer Registry | 4103 | 58,706 | Epithelial ovarian cancer | The Danish Prescription Registry | Use < 2 prescriptions (non-users) | 1,5,7,25,29,43,50,52,55, 56,57,58, | 8 |
Lo-Ciganic WH [158], 2012, US | F | 2003–2008 | HOPE study | 625 | 1210 | Ovarian cancer | Questionnaire | Use at least 2 tablets per week for 6 months or more(regular) | 1, 5,7,10,11,30,39,42,49,50,55,59,60 | 7 |
Ammundsen HB [159], 2012, Denmark | F | 1995–1999 | Danish MALOVA study | 756 | 1564 | Ovarian cancer | Questionnaire | Use two times or more per week for more than 1 month | 1,38,50,55,61 | 6 |
Pinheiro SP [160], 2010, US | F | 1992–2003 | New England Case-Control Study | 1120 | 1160 | Ovarian cancer | Questionnaire | Use at least twice aweek(regular) | 1, 54 | 7 |
Wu AH [161], 2009, US | F | 1998–2002 | Population from Los Angeles County | 582 | 668 | Ovarian cancer | Questionnaire | Use aspirin medication 2 or more times a week for 1 month or longer | 1,4,5,11,49, 50,51,55, 62 | 8 |
Wernli KJ [162], 2008, US | F | 1998–2001 | Population from Wisconsin and Massachusetts | 400 | 2107 | Ovarian cancer | Telephone interview | Use aspirin for more than 6 months and more than twice per week(ever use) | 1,4,30, 43,49,51 | 7 |
Merritt MA [163], 2008, Australia | F | 2002–2005 | Australian Ovarian Cancer Study | 1564 | 1502 | Ovarian cancer | Self-administered questionnaires | Ever use of aspirin-not further defined | 1,5,50,55 | 6 |
Schildkraut JM [164], 2006, US | F | 1999–2003 | North carolina ovarian cancer study | 586 | 627 | Ovarian cancer | In-person questionnaires | Use at least 3 month of use during the 5-year period(regular) | 1,4,5,11,43,49, 50,53,60,63,64 | 7 |
Moysich KB [165], 2001, US | F | 1982–1998 | RPCI buffalo | 547 | 1094 | Ovarian cancer | Self-administered questionnaires | Use at least once a week for 6 consecutive months(regular) | 1,4, 40,49,55, 65 | 6 |
Rosenberg L [166], 2000, US | F | 1976–1998 | Patients from hospital in Baltimore, Boston, New York, and Philadelphia | 780 | 4623 | Ovarian cancer | Questionnaire | Use at least 1 day per week for at least 6 months(regular) | 1,30,59 | 7 |
Tavani A [167], 2000, US | F | 1992–1999 | Population from Italy | 749 | 898 | Ovarian cancer | Questionnaires | Use at least once a week for more than six consecutive months(regular) | 1,5,10,37,50,54, 55,59 | 6 |
Cramer DW [168], 1998, US | F | 1992–1997 | Patients from hospital in eastern Massachusetts and all of New Hampshire | 563 | 523 | Ovarian cancer | In-person interviews | Use at least once a week for at least 6 months | 1,5,9,46,54,55,66,67,68 | 8 |
Cohort studies | ||||||||||
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 445 | 116,248 | Ovarian cancer | Questionnaire | Use at both baseline and year 3 visits (consistent) | 1,3,4,5, 6, 10,11,18,19,22,24,25,29,30,31,,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47 | 9 |
SetiawanVW [169], 2012, Multinational | F | 1993–2008 | MEC | 275 | 64,000 | Ovarian cancer | Questionnaire | Use at least 2 times a week for 1 month or longer | 1,11,25,36,50, 55 | 7 |
Murphy MA [170], 2012, US | F | 1995–2006 | AARP | 438 | 96,710 | Ovarian cancer | Mailed questionnaires | Use one or more pills per week(regular) | 1,4,11,25,36,37,43,50,55, | 7 |
Prizment AE [171], 2010, US | F | 1992–2006 | IWHS | 157 | 21,694 | Ovarian cancer | Questionnaire | Had ever taken aspirin- not further defined | 1,10,25,45,55,69 | 9 |
Pinheiro SP [160], 2010, US | F | 1992–2003 | NHS and NHS-II cohorts | 217 | 628 | Ovarian cancer | Questionnaire | Use at least twice a week(regular) | 1,25,51 | 7 |
Lacey JV [172], 2004, US | F | 1979–1998 | BCDDP | 116 | 31,364 | Ovarian cancer | Telephone interview and mailed questionnaires | Use at least once a week for 1 year(regular) | 1,4,10,11,42,50,51,55 | 7 |
Friis S [62], 2003, Denmarka | F | 1989–1997 | Population from North Jutland County | 34 | 29,470 | Ovarian cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Akhmedkhanov A [173], 2001, US | F | 1994–1996 | The NYU Women’s Health Study | 68 | 680 | Epithelial ovarian cancer | Self-administered questionnaires | Use three or more times per week for at least 6 months | 4,36,50, 55 | 8 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Brons N [174], 2015, Denmark | F | 2000–2009 | Patients from Civil Registration System | 5382 | 72,127 | endometrial cancer | Prescription | Use ≥2 prescriptions on separate dates over the entire study period(ever users) | 1,5,25,29,48,49,50,51 | 8 |
Neill AS [175], 2013, Australia | F | 2005–2007 | ANECS | 1360 | 712 | endometrial cancer | Telephone interview | Had ever taken aspirin- not further defined | 1,3,10,25,36,48,50,52 | 7 |
Bosetti C [176], 2010, Italy | F | 1992–2006 | Population from Italy | 442 | 676 | Endometrial Cancer | Questionnaire | Use at least once a week for more than 6 months(regular) | 1,5,10,25,36,48, 52,53,54,55 | 5 |
Fortuny J [177], 2009, US | F | 2001–2005 | The EDGE Study | 469 | 467 | endometrial cancer | Interview | Use aspirin for 6 months or longer | 1,10 | 7 |
Bodelon C [178], 2009, US | F | 2003–2005 | Population from King, Pierce, and Snohomish counties | 330 | 286 | Endometrial Cancer | In-person interview | Use for more than 5 days per month for at least 6 months | 1,7,10,25,30 | 6 |
Moysich KB [179], 2005, US | F | 1982–1998 | RPCI Institute | 427 | 427 | Endometrial Cancer | Questionnaire | Use at least once a week for 6 months (regular) | 1,5,10,36,37,48 | 6 |
Cohort studies | ||||||||||
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 865 | 85,351 | Endometrial cancer | Questionnaire | Use at both baseline and year 3 visits (consistent) | 1,3,4,5, 6, 10,11,18,19,22,24,25,29,30,31, 32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47 | 9 |
Brasky TM [180], 2013, US | F | 2000–2010 | VITAL Cohort | 248 | 22,268 | Endometrial Cancer | Mailed baseline questionnaire | Use≥4 days/week and ≥ 4 years(high use) | 1,3,4,5,6,10,11,18,25,29,31,36.37,39,45,47,48, 50,57,58,59 | 7 |
SetiawanVW [169], 2012, Multinational | F | 1993–2008 | MEC | 620 | 64,000 | Endometrial cancer | Questionnaire | Use at least 2 times a week for 1 month or longer | 1,3,10,11,25,36,48,52,. | 7 |
Prizment AE [171], 2010, US | F | 1992–2006 | IWHS | 311 | 21,694 | Endometrial cancer | Questionnaire | Had ever taken aspirin- not further defined | 1,6,10,25,36,37,50,52, 56 | 9 |
Danforth KN [181], 2009, US | F | 1995–2003 | AARP | 576 | 72,524 | Endometrial cancer | Mailed questionnaire | Had ever taken aspirin- not further defined | 3,4,10,11,18,36,37,45,48,50,52,56 | 7 |
Viswanathan AN [182], 2008, USa | F | 1980–2004 | The NHS | 436 | 82,971 | Endometrial cancer | Medical record | Use at least 1 tablet per week or 1 day per week(current user) | 4,10,18,25,37,40,60,61,62 | 6 |
Friis S [62], 2003, Denmarka | F | 1989–1997 | Population of North Jutland County | 45 | 29,470 | Endometrial cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | F | 1971–1987 | The National Health and Examination Survey Ι | 26 | 12,668 | Endometrial cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Friel G [183], 2015, US | F | 1982–1998 | RPCI | 272 | 1072 | Cervical Cancer | Questionnaire | Use at least once a week for 6 months(regular) | 1,3,4,5, 6,7,8,9,10,11,12,13 | 7 |
Cohort studies | ||||||||||
Wilson JC [184], 2013, UKa | F | 1995–2010 | CPRD | 724 | 3479 | Cervical Cancer | Prescription database | Use of aspirin - not further defined | 3,14,15,16,17,18,19,20,21 | 7 |
Friis S [62], 2003, Denmarka | F | 1989–1997 | Population from North Jutland County | 15 | 29,470 | Cervix uterus cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | F | 1971–1987 | The National Health and Examination Survey Ι | 29 | 12,668 | Cervix uterus cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Iqbal U [47], 2017, China | M | 2001–2011 | The Taiwan NHI database | 32,419 | 129,676 | Prostate cancer | Prescription | Patients had aspirin prescribed at least for 2 months during the 3-year period before the initial cancer diagnosis | 1,2,13,14, 15,16,17 | 7 |
Skriver C [185], 2016, Denmark | M | 2000–2012 | Danish nationwide registries | 35,600 | 177,992 | Prostate cancer | Prescription | Use aspirin ≥ 2 prescriptions redeemed on separate dates(ever use) | 1, 4,14,28,30,36,37,38,,40, | 8 |
Veitonmäki T [186], 2013, Finland | M | 1995–2002 | Finnish Cancer Registry | 13,478 | 24,657 | Prostate cancer | Prescription database | Ever use aspirin- not further defined | 1,32 | 8 |
Murad AS [187], 2011, UK | M | 2001–2008 | ProtecT | 1016 | 5043 | Prostate cancer | Questionnaire | Ever use aspirin- not further defined | 1,28,33,35 | 8 |
Salinas CA [188], 2010, US | M | 2002–2005 | SEER cancer registry | 1000 | 942 | Prostate cancer | Questionnaire | Use at least once per week for 3 months(ever use) | 1,11,42 | 7 |
Harris RE [189], 2007, US | M | 1999–2005 | CHRI | 24 | 39 | Prostate cancer | Medical-record | At least two times per week for 2 years or more | 1,3,5,6,10 | 5 |
Bosetti C [190], 2006, Italy | M | 1991–2002 | Population from the greater Milan area, the provinces of Pordenone, Gorizia, Latina and the urban area of Naples | 1261 | 1131 | Prostate cancer | Standard questionnaire | Use at least once a week for more than 6 months (regular) | 1,4,5,34 | 5 |
Dasgupta K [191], 2006, Canada | M | 1999–2002 | RAMQ | 2025 | 2150 | Prostate cancer | Prescription database | Did not receive any prescription for aspirin (nonuser) | 1,43 | 6 |
Liu X [192], 2006, US | M | 2001–2004 | Population from Cleveland, Ohio | 471 | 468 | Prostate cancer | Personal interview | Use at least twice a week for more than a month(any use) | 1,11,44 | 5 |
Menezes RJ [193], 2006, US | M | 1982–1998 | RPCI | 1029 | 1029 | Prostate cancer | Questionnaire | Use at least once a week for at least 6 months (regular) | 1,5,10 | 5 |
Perron L [194], 2003, Canada | M | 1993–1995 | RAMQ | 2221 | 11,105 | Prostate cancer | Prescription database | Ever use aspirin- not further defined | 1,50 | 6 |
Norrish AE [195], 1998, New Zealand | M | 1996–1997 | Auckland Prostate Study | 317 | 480 | Prostate cancer | Questionnaire | At least once per week(regular) | 1,50,51,52,53 | 7 |
Neugut AI [80], 1998, US | M | 1989–1992 | Columbia-Prebyterian Medical Center | 319 | 189 | Prostate cancer | Medical record | Use aspirin-not further defined | 1,4,5 | 6 |
Cohort studies | ||||||||||
Cao Y [8], 2016, US | M | 1980–2010 1986–2012 | NHS and HPFS | 1019 | 135,965 | Prostate cancer | Questionnaire | Use at least 2 times per week(regular) | 3,5,6,7,8,9,10,11,12,18,19,20,21,22,23,24,25,70 | 9 |
Lapi F [196], 2016, Italya | M | 2002–2013 | HSD | 187 | 13,453 | Prostate Cancer | Prescription database | Use low-dose aspirin-not further defined | 1,3,6,9,13,14,16,28,38,54,55,56,57 | 8 |
Nordström T [197], 2015, Swedena | M | 2007–2012 | Population from Stockholm County, Sweden | 8430 | 204,241 | Prostate cancer | Swedish Prescribed Drug Register | Any dispensed prescription of the drug within 2 years before biopsy | 1,4,13,14, 58,59,60 | 5 |
Hollestein LM [91], 2014, Netherlandsa | M | 1998–2010 | PHARMO and the Eindhoven Cancer Registry | 882 | 53,679 | Prostate cancer | Prescription database | Low dose aspirin (≤ 100 mg daily)- not further defined | 1,2,26,27 | 8 |
Shebl FM [198], 2012, US | M | 1993–2001 | PLCO | 3573 | 29,450 | Prostate cancer | Questionnaire | Regular use aspirin-not further defined | 5,11,34, 42,62 | 7 |
Mahmud SM [199], 2011, Canadaa | M | 1985–2000 | Saskatchewan Ministry of Health (SH) databases and the Saskatchewan Cancer Registry (SCR). | 9007 | 35,891 | Prostate cancer | Prescription database | Had a participant ever filled a prescription of aspirin in the index class at any time during his exposure history | 28,41,42 | 6 |
Brasky TM [200], 2010, US | M | 2000–2007 | VITAL Cohort | 1547 | 34,132 | Prostate cancer | Questionnaire | Use aspirin ≥1 day/ week for ≥ 1 year(regular) | 1,4,5,9,10,11,19,30,55, 65,66,67 | 5 |
Siemes C [96], 2008, Netherland | M | 1992–2004 | The Rotterdam Study | 216 | 7621 | Prostate cancer | Questionnaire and prescriptions | The absence of a prescription for any non-aspirin or aspirin NSAID(no use) | 1,3,10,61 | 8 |
Jacobs EJ [98], 2007, US | M | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 5539 | 69,810 | Prostate cancer | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,3,4,9,10,11,18, 20,28,29,30,31 | 8 |
Platz EA [201], 2005, US | M | 1980–2004 | BLSA | 141 | 9748 | Prostate cancer | Self-reported | Had ever taken aspirin-not further defined | 1,28,45,68 | 7 |
García Rodríguez LA [44], 2004, UKa | M | 1995–2001 | GPRD | 2096 | 9579 | Prostate cancer | Prescription database | No use of aspirin at any time before the index date(nonuser) | 1,45,46,47,48,49 | 8 |
Friis S [62], 2003, Denmarka | M | 1989–1997 | Population of North Jutland County | 196 | 29,470 | Prostate cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Habel LA [202], 2002, US | M | 1964–1973 | The Kaiser Permanente Medical Care Program in Northern California | 2574 | 90,100 | Prostate cancer | Questionnaire | Use more than six aspirin per days | 1,4,11,69 | 6 |
Schreinemachers DM [63], 1994, US | M | 1971–1987 | The National Health and Examination Survey Ι | 123 | 12,668 | Prostate cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Paganini-Hill A [103], 1989, US | M | 1981–1988 | Population from Leisure World, Laguna Hills, US | 149 | 13,870 | Prostate cancer | Questionnaire | Aspirin use: none,<daily, daily | 2 | 4 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Karami S [203], 2016, US | M/F | 2002–2007 | US Kidney Cancer Study | 1187 | 1204 | Renal-cell cancer | Questionnaires | Use at least once a week for 3 months or longer, at least 2 years prior to the interview | 1,2,3,4,5,10,11, 27,51,52 | 8 |
Tavani A [204], 2010, Italy | M/F | 1992–2004 | Population from Italian areas | 755 | 1297 | Renal-cell cancer | Questionnaires | Use at least once a week for more than 6 months(regular) | 1,2,3,5,6,7,27,55,56 | 7 |
Gago-Dominguez M [205], 1999, US | M/F | 1986–1994 | Patients from Los Angeles County | 1204 | 1204 | Renal-cell cancer | Questionnaires | Had ever taken the drug 20 or more times | 3,5,10,27,57 | 6 |
Chow WH [206], 1994, US | M/F | 1988–1990 | Population from Minnesota | 440 | 691 | Renal-cell cancer | Interviewer | Use at least 2 or more times per week for 1 month or longer (regular) | 1,3,10 | 6 |
McCredie M [207], 1993, Austrilia | M/F | 1989–1990 | The NSW Central Cancer Registry | 489 | 523 | Renal-cell cancer | Questionnaires | Had ever taken the drug 20 or more times | 1,2,3,50,58, | 7 |
McCredie M [208], 1988, Austrilia | M/F | 1977–1982 | New South Wales Central Cancer Registry | 360 | 985 | Kidney cancer | Questionnaires | Had taken a total of more than 0.1 kg | 1,2,3,44,59,60,61 | 6 |
Cohort studies | ||||||||||
Karami S [203], 2016, US | M/F | 2002–2007 | Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial | 135 | 98,807 | Renal cell carcinoma | Questionnaires | Use at least once per week | 1,3,5,10,11,27,51 | 7 |
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 329 | 141,880 | Kidney cancer | Questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5, 6,10,11,17,18,19,25,26,28,29,30,31,32,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48 | 9 |
Liu W [209], 2013, US | M/F | 1996–2006 | AARP | 884 | 298,468 | Renal cell carcinoma | Questionnaires | Any use of aspirin | 1,2,3,4,5,6,7,10,11,18,27,53,54 | 7 |
Cho E [210], 2011, US | F | 1986–2006 | NHS | 153 | 77,525 | Renal cell carcinoma | Questionnaires | Use aspirin ≥2 times/week(regular) | 1,3,6,10,18,19,27,39 | 7 |
M | 1990–2006 | HPFS | 180 | 49,403 | Renal cell carcinoma | Questionnaires | Use aspirin ≥2 times/week(regular) | 1,3,6,10,18,19,27 | 9 | |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 365 | 146,113 | Kidney cancer | Questionnaires | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,7,10,11, 15,16,17,18,20,25, 27,45 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 67 | 29,470 | Kidney cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 32 | 12,668 | Kidney cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Paganini-Hill A [103], 1989, US | M/F | 1981–1988 | Population from Leisure World, Laguna Hills, US | 25 | 13,870 | Kidney cancer | Questionnaires | Aspirin use: none,<daily, daily | 2 | 4 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Linet MS [211], 1995, US | M/F | 1983–1986 | Cancer registries in New Jersey,Iowa and Los Angeles | 418 | 405 | Renal pelvis and ureter cancer | Questionnaire | Use 2 or more doses per week for at least 1 month or longer(regular) | 1,2,3,7 | 8 |
Mccredie M [207], 1993, Australia | M/F | 1989–1990 | The NSW Central Cancer Registry | 147 | 523 | Renal pelvis cancer | Questionnaire | Had ever taken the drug 20 or more times | 1,2,3,5,8 | 7 |
Ross RK [212], 1989, US | M/F | 1978–1982 | The Cancer Surveillance Program in Los Angeles County | 187 | 187 | Renal pelvis and ureter cancer | Telephone interviews | Use aspirin for more than 30 days in a single year | 1,2,6 | 8 |
Jensen OM [213], 1989, Denmark | M/F | 1979–1982 | Patients in hospitals of Copenhagen | 90 | 251 | Renal pelvis and ureter cancer | Face-to-face interviews | Use of aspirin - not further defined | 1,2,4 | 7 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Baris D [214], 2013, US | M/F | 2001–2004 | Population from Maine, Vermont and New Hampshire | 783 | 890 | Bladder cancer | Self-reported | Use at least 20 times(any) | 1,2,3,11,26,51 | 6 |
Fortuny J [215], 2007, US | M/F | 1998–2001 | The New Hampshire State Department of Health and Human Services’ rapid reporting Cancer Registry | 456 | 369 | Bladder cancer | Interview | Use at least four times a week for 1 month or longer prior to the reference date | 1,2,3,25 | 7 |
Fortuny J [216], 2006,Spain | M/F | 1997–2000 | Patients from five regions in Spain (Barcelona, Valle’s/Bages, Alacant, Tenerife, and Asturias) | 907 | 965 | Bladder cancer | Self-reported | Use twice or more weekly for ≥ 1 month (regular) | 1,2,3,25,26,52,53 | 8 |
Castelao JE [217], 2000, US | M/F | 1987–1996 | SEER cancer registry | 1514 | 1514 | Bladder cancer | Questionnaire | Use at least 20 times(any) | 3,5,53,54,55,56, 57,58,59,60 | 7 |
Steineck G [218], 1995, Sweden | M/F | 1985–1987 | Population from the County of Stockholm | 325 | 393 | Bladder cancer | Questionnaire | Had ever taken aspirin-not further defined | 1,2,3,55,56,61,62,63 | 5 |
Cohort studies | ||||||||||
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 175 | 142,330 | Bladder cancer | Questionnaire | Use at both baseline and year 3 visits (consistent) | 1,3,4,5,6,10,11,17,18,19,25,26,,28,29,30,31,32,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48 | 9 |
Shih C [219], 2013, US | M/F | 2000–2010 | The VITAL cohort | 344 | 77,048 | Bladder cancer | Questionnaire | Use at least once per week, for at least 1 year | 1,2,3,4,5,11,49 | 8 |
Daugherty SE [220], 2011, US | M/F | 1995–1996 | AARP | 1660 | 334,908 | Bladder cancer | Questionnaire | Use aspirin ≥ 2times/week (regular) | 3,10,11,25,27 | 7 |
1993–2001 | PLCO Cancer Screening | 704 | 154,952 | Bladder cancer | Questionnaire | Use aspirin ≥ 2times/week (regular) | 3,10,11,25,27 | 7 | ||
1994–1998 | The USRT Study | 97 | 90,972 | Bladder cancer | Questionnaire | Use aspirin ≥ 2times/week (regular) | 3,10,11,25,27 | 7 | ||
Genkinger JM [221], 2007, US | M | 1986–2004 | HPFS | 392 | 49,448 | Bladder cancer | Questionnaire | Use 2 or more times per week(regular) | 1,3,26,50 | 9 |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 867 | 146,113 | Bladder cancer | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,7,10,11, 15,16,17,18,22, 25,45, 63 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population of North Jutland County | 161 | 29,470 | Bladder cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 35 | 12,668 | Bladder cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Paganini-Hill A [103], 1989, US | M/F | 1981–1988 | Population from Leisure World, Laguna Hills, US | 96 | 13,870 | Bladder cancer | Questionnaire | Aspirin use: none,<daily, daily | 2 | 4 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Egan KM [41], 2016, US | M/F | 2004–2012 | Population in Southeastern US | 1433 | 1296 | Brain tumor | Interview | Use at least twice a week for 12 consecutive months (regular) | 1,2,5,7,8 | 6 |
Gaist D [222], 2013, Denmark | M/F | 2000–2009 | Danish Cancer Registry, Civil Registration System, National Prescription Registry, Danish National Registry of Patients, and Danisheducation and fertility registries within Statistics Denmark | 2688 | 18,848 | Glioma | National Prescription Registry | Use aspirin as a ‘low’ (≤ 100 mg) or ‘high’ (150 mg) daily dose of low-dose aspirin | 5,10,13,14,15,16,17,18 | 7 |
Ferris J [223], 2012, US | M/F | 2007–2010 | CUMC | 236 | 230 | Glioma | Questionnaire | Use at least twice a weekfor 6 months or longer(ever use) | 1,2,7,9,11,12,13 | 7 |
The UCSF | 281 | 170 | Glioma | Questionnaire | Use at leasttwice a week for 6 months or longer(ever use) | 1,2,7,9,11,12,13 | ||||
Cohort studies | ||||||||||
Bannon FJ [224], 2013, UKa | M/F | 1987–2009 | UK Clinical Practice Research Datalink(CPRD) | 5052 | 42,678 | Brain tumor | Prescription database | Had ever taken aspirin- not further defined | 1,2,8 | 7 |
Daugherty SE [225], 2011, US | M/F | 1996–2006 | AARP | 605 | 302,767 | Glioma | Questionnaire | Use aspirin ≥ 2 times/wk.(regular) | 1,2,7,19 | 7 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 70 | 29,470 | Brain tumor | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Di Maso M [226], 2015, Italy | M/F | 1992–2008 | Population from Aviano, Pordenone and the greater Milan area in northern Italy | 198 | 596 | Nasopharyngeal cancer | Questionnaire | Use at least one aspirin a week for at least 6 months(regular) | 1,2,3,5,11,12,13 | 6 |
Becker C [227], 2015, UK | M/F | 1995–2013 | CPRD | 2745 | 16,470 | Head and neck cancer | Prescription database | Use aspirin ≥1 Prescription | 3,6,8,10 | 7 |
Macfarlane TV [228], 2012, Europe | M/F | ARCAGE | 1779 | 1993 | Head and neck cancer | Questionnaire | Use at least once a weekfor a year(regular) | 1,2,3,5,6,10,18 | 7 | |
Ahmadi N [229], 2010, US | M/F | 2003–2007 | Patients from the Lombardi Comprehensive Cancer Center, at GUMC | 25 | 25 | Head and neck cancer | Questionnaire | Daily use of aspirin | 5,19 | 5 |
Jayaprakash V [230], 2006, US | M/F | 1982–1998 | RPCI | 529 | 529 | Head and neck cancer | Questionnaire | Had ever taken aspirin before the onset of the present illness | 1,2,3,6 | 7 |
Rosenquist K [231], 2005, Sweden | M/F | 2000–2004 | Population from the Southern healthcare region of Sweden | 132 | 320 | Oral and oropharyngeal squamous cell carcinoma | Interview | Had ever taken aspirin-not further defined | 3,6 | 6 |
Bosetti C [232], 2003, Italy | M/F | 1992–2000 | Population from Italy | 740 | 1779 | Oral and pharyngeal, laryngeal cancer | Questionnaire | Use at least once a week for more than 6 months | 1,2,3,5,6,11 | 6 |
Cohort studies | ||||||||||
Macfarlane TV [69], 2014, UKa | M/F | 1996–2010 | PCCIU database | 1195 | 3580 | Head and neck cancer | Prescription database | Had at least one Prescription (users) | 1,2,8,14,15,16,17 | 7 |
Wilson JC [233], 2013, US | M/F | 1993–2001 | PLCO | 316 | 142,034 | Head and neck cancer | Questionnaire | Use aspirin regularly -not further defined | 1,2,3,10 | 7 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 68 | 29,470 | Head and neck cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Cohort studies | ||||||||||
Patel D [234], 2015, US | M/F | 1993–2001 | AARP | 292 | 269,553 | Thyroid cancer | Questionnaires | Use aspirin ≤ 2 times/Week(no regular use) | 2,3,6,8,11 | 7 |
PLCO | 56 | 58,433 | Thyroid cancer | Questionnaires | Use aspirin ≤ 2 times/Week(no regular use) | 2,3,6,8,11 | 6 | |||
U.S. Radiologic Technologists Study | 133 | 60,591 | Thyroid cancer | Questionnaires | Use aspirin ≤ 2 times/Week(no regular use) | 2,3,6,8,11 | 6 | |||
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 229 | 142,330 | Thyroid cancer | Questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5,6,7,9,10,11,12,13,14,15,16,17,18,19,22,24,25,26,27,28,29,30,31,32,33,34,35,36,37 | 9 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Reinau D [235], 2015, UK | M/F | 1995–2013 | GPRD | 73,262 | 96,854 | Skin cancer | Prescription database | Last prescription ≤ 1 year before the index date(current user) | 3,6,10, 29,43,47,48,49,50,51,52 | 8 |
Johannesdottir SA [236], 2012, Denmark | M/F | 1991–2009 | Population from northern Denmark | 18,532 | 178,655 | Skin cancer | Prescription records | Redeemed > 2 prescriptions during the entire study period | 1,2,20,44,45,46 | 8 |
Torti DC [237], 2011, US | M/F | 1997–2000 | Population from New Hampshire and bordering regions | 1022 | 1484 | Skin cancer | Interview | Use at least four times a week for at least 1 month | 1,2,3,53,54,55 | 8 |
Curiel-Lewandrowski C [238], 2011, US | M/F | 2004–2007 | Dana Farber Harvard Cancer Center Institutions and Dermatology Associates of Concord, Boston(USA) | 400 | 600 | Cutaneous melanoma | Telephone interview | Use at least once weekly within a year preceding the interview (current user) | 56 | 8 |
Jeter JM [239], 2011, US | M/F | 2000–2003 | The GEM study | 327 | 119 | Melanoma | Self-reported | Daily basis for at least 3 months | 1,2,4,53,57 | 6 |
Asgari MM [240], 2010, US | M/F | 1994–2004 | KPNC | 415 | 415 | Cutaneous squamous sell sarcinoma | Questionnaire | Use at least once a week for at least 1 year(regular) | 3,4,5,30,53,56,58,59,60,61,62,63,64,65,66,67,68 | 8 |
Cohort studies | ||||||||||
Hollestein LM [91], 2014, Netherlandsa | M/F | 1998–2010 | PHARMO and the Eindhoven Cancer Registry | 2363 | 109,276 | Skin cancer | Prescription database | Low dose aspirin (≤ 100 mg daily)- not further defined | 1,2,11,12 | 8 |
Wysong A [241], 2014, US | F | 1993–1998 | WHI | 7652 | 54,728 | Non-melanoma skin cancer | Questionnaire | Use ≥ 2 times/week for at least 2 weeks(regular) | 1,3,5,7,10,14,15,19,21,29,43,69,70,71,72,73,74 | 6 |
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 585 | 142,330 | Melanoma | Self-administered questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5,6,10,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37 | 9 |
Jeter JM [242], 2012, US | F | 1980–2008 | NHS | 17,074 | 92,125 | Skin cancer | Questionnaire | Use at least 1–2 tablets/week or 1 day/week of regular use at any lifetime(current user) | 1,3,4,7,10,14,15,54,57,75,76,77,78,79 | 7 |
Cahoon EK [243], 2012, US | M/F | 1994–1998 2003–2005 | United States Radiologic Technologists study | 2215 | 58,213 | Basal cell carcinoma | Questionnaire | Use at least 1 days per month in the past year | 1,2,80 | 8 |
Asgari MM [244], 2008, US | M/F | 2000–2005 | The VITAL cohort | 216 | 39,909 | Melanoma | Questionnaire | Use at least once a week for a year in the 10-year period before baseline(ever use) | 1,2,4,5,7,15,29, 30,56,59,69,73,81,82,83 | 8 |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 1049 | 146,113 | Melanoma | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,10,13,14,18,19,36,38,39,40,41,42 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 69 | 12,668 | Melanoma | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Baecklund E [245], 2006, Swedish | M/F | 196–1995 | From the Swedish Inpatient Register | 269 | 225 | Lymphoma | Hospital records | Use aspirin for 4 consecutive weeks | 15,16 | 5 |
Zhang YQ [246], 2006, US | M/F | 197–2002 | Subjects were recruited from patients admitted to hospitals in New York, Philadelphia, Boston and Baltimore | 412 | 1524 | Non-Hodgkin lymphoma | Nurse-interviewers administered standard questionnaires | Use at least four times per week for at least three or more continuous months(regular) | 1,2,7,8 | 7 |
Flick ED [247], 2006, US+ | M/F | 200–2004 | Population from the California counties of San Francisco, Alameda, Marin, Contra Costa, San Mateo, and Santa Clara | 604 | 638 | Non-Hodgkin lymphoma | Interview | Use at least 2 days per week for 3 months or longer during the past 20 years | 1,2,17 | 7 |
Baker JA [248], 2005, US | M/F | 198–1998 | RPCI | 628 | 2512 | Non-Hodgkin lymphoma | Questionnaire | Use at least once per week for 6 months | 1 | 5 |
Chang ET [249], 2004, US | M/F | 1997–2000 | population from the greater Boston, Massachusetts, metropolitan area and in the state of Connecticut | 565 | 679 | Hodgkin’s lymphoma | Telephone interview | Use two or more tablets per Week(regular) | 1,2,3,9,17 | 6 |
Zhang YW [250], 2004, US | M/F | 1996–2000 | Patients in Yale Cancer Center’s Rapid Case Ascertainment Shared Resource(RCA) | 601 | 717 | Non-Hodgkin lymphoma | Iinterview | Use at least once a day for a period of 6 months or longer previous to 1 year ago | 1,4,10,18 | 7 |
Cohort studies | ||||||||||
Hollestein LM [91], 2014, Netherlands a | M/F | 1998–2010 | PHARMO and the Eindhoven Cancer Registry | 256 | 109,276 | Lymphoma | Prescription database | Low dose aspirin (≤100 mg daily)- not further defined | 1,2,11,12 | 8 |
Birmann BM [251], 2014, US | F | 1976–2008 | NHS | 196 | 85,942 | Multiple myeloma | Questionnaire | 81-mg “baby” and 325-mg “adult” strength | 1,10 | 8 |
M | 1986–2008 | HPFS | 132 | 47,029 | Multiple myeloma | Questionnaire | 81-mg “baby” and 325-mg “adult” strength | 1,10 | 8 | |
Teras LR [252], 2013, US | M/F | 1992–2007 | The CPS-II Nutrition Cohort Cancer Prevention Study-II (CPS-II) Nutrition Cohort | 1709 | 149,570 | Lymphoma | Questionnaire | Use aspirin ≥30 aspirin pills/Month(regular) | 1,3,4,5,6,10,19,20, 21,22,23,24,25 | 7 |
Chang ET [253], 2011, Denmarka | M/F | 1995–2008 | Population from Denmark | 1659 | 8089 | Hodgkin lymphoma | Prescription database | Use aspirin ≥ 2 times per week | 1,2,13,14 | 8 |
Walter RB [254], 2011, US | M/F | 2000–2002 | VITAL Study | 224 | 64,839 | Lymphoma | Questionnaire | Had ever taken low dose aspirin(81 mg) | 4,21,23,26,27,28,29,33 | 6 |
Erber E [255], 2009, US | M/F | 199–1996 | MEC Study | 896 | 193,050 | Non-Hodgkin Lymphoma | Self-completed questionnaire | Use at least two times per week for 1 month or longer | 5,6,10 | 8 |
Cerhan JR [256], 2003, US | M/F | 199–1999 | IWHS | 130 | 27,290 | Non-Hodgkin Lymphoma | Self-completed questionnaire | Had ever taken aspirin- not further defined | 1,3,6,17,21,25, 29,30,31,32 | 7 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 57 | 29,470 | Non-Hodgkin’s lymphoma | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 48 | 12,668 | Lymphoma | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Ross JA [257], 2011, US | M/F | 2005–2009 | The MCSS | 734 | 697 | Leukemia | Questionnaire | Use at least once per week for at least 1 year | 1,7,10 | 9 |
Weiss JR [258], 2006, US | M/F | 1981–1998 | RPCI | 169 | 676 | Leukemia | Questionnaire | Use at least once per week for 6 months(regular) | 1,2 | 6 |
Oleske D [7], 1985, US | M/F | 1975–1981 | Hairy Cell Tumor Registry and Treatment Center | 45 | 134 | Leukemia | Questionnaire | Use three times a week or more for more than 2 months | 1,2,6,11 | 6 |
Cohort studies | ||||||||||
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 465 | 146,113 | Leukemia | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,10,11,12,13,14,15,16,17,18,19 | 8 |
Kasum CM [259], 2003, US | F | 1992–2000 | IWHS | 81 | 28,224 | Leukemia | Questionnaire | Had ever taken aspirin- not further defined | 1,3,5 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 69 | 29,470 | Leukemia | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 39 | 12,668 | Leukemia | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Rinzivillo M [260], 2016, Italy | M/F | 2009–2012 | Population from Universities of Rome and Bologna and at the European Institute of Oncology | 215 | 860 | Small Intestine Neuroendocrine Tumors | Questionnaire | Use at any dose at least twice a week for more than one consecutive year | 1,2, | 7 |